<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00200538</url>
  </required_header>
  <id_info>
    <org_study_id>BRD 05/1-E</org_study_id>
    <nct_id>NCT00200538</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients</brief_title>
  <official_title>Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the efficacy and tolerability of memantine&#xD;
      (anti-excitotoxic, neuroprotective treatment currently used in Alzheimer's disease [AD]) in&#xD;
      frontotemporal dementia patients after a one-year treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Frontotemporal dementia (FTD) is the first cause of dementia in the presenium&#xD;
      (onset before the age of 65 years). Characterized by behavioral disorders, it is often more&#xD;
      incapacitating than Alzheimer's disease (AD), and leads to death within 7 years on average&#xD;
      (9-10 years for AD). It affects young individuals (on average, 20 years younger than in AD),&#xD;
      who are often still active. Management of these patients is therefore burdensome and complex.&#xD;
      As opposed to AD, however, no treatment is currently available. Few therapeutic trials have&#xD;
      actually been conducted on this disorder. Many reasons may account for this:&#xD;
&#xD;
        1. recent availability of reliable diagnostic criteria (the Lund and Manchester groups'&#xD;
           consensus statement in 1994; revised in 1998),&#xD;
&#xD;
        2. the very small number of cases as opposed to AD-the number of cases was estimated at&#xD;
           approximately 3,500 vs 600,000, for AD, in France in 2004-, FTD therefore falls into the&#xD;
           category of rare diseases (i.e., less than 30,000 cases),&#xD;
&#xD;
        3. the scarcity of valuable physiopathological hypotheses.&#xD;
&#xD;
      Besides a non-specific serotoninergic dysfunction, no significant anomalies related to&#xD;
      particular neuromediators have apparently been found (as opposed to AD, which is&#xD;
      characterized by a cholinergic deficit). In 1998, the discovery of mutations in the Tau gene&#xD;
      in certain kindreds showing a dominant autosomal transmission of FTD, oriented research&#xD;
      efforts toward the tau protein and provided new perspectives. Many studies have suggested the&#xD;
      role of excitotoxicity. Abnormal aggregation of the tau protein has been observed in the&#xD;
      brains of a majority of FTD patients (familial and sporadic form). Excitotoxicity may be&#xD;
      responsible for promoting this abnormal aggregation through modification of the expression&#xD;
      and phosphorylation state of the tau protein. The hypothesis of this study is that an&#xD;
      anti-excitotoxic neuroprotective treatment may slow the pathogenic process and therefore be&#xD;
      an effective treatment for this pathology.&#xD;
&#xD;
      Goals: To assess the efficacy and tolerability of memantine (anti-excitotoxic,&#xD;
      neuroprotective treatment currently used in AD) in FTD patients after a one-year treatment.&#xD;
&#xD;
      Type of study: National, multicenter, randomized, double-blind, parallel group,&#xD;
      placebo-controlled, phase II therapeutic trial.&#xD;
&#xD;
      Study design: Sixty four (64) patients, aged 45 to 75 years, will be enrolled in the study&#xD;
      for a period of 12 months (clinical inclusion criteria are defined based on the Lund and&#xD;
      Manchester group consensus statement [revised version 1998]), and followed up for 1 year in a&#xD;
      controlled study. At the time of inclusion, the Mini Mental Status Examination (MMSE) score&#xD;
      should be at least 19 (below 18, a neuropsychological examination is impossible). Patients&#xD;
      will either take memantine, or a placebo (randomization ratio of 1:1) twice a day (i.e., 20&#xD;
      mg of memantine per day in the memantine arm). The primary efficacy variable will be a global&#xD;
      assessment tool, the CIBIC-Plus (Clinician's Interview-Based Impression of Change Plus&#xD;
      Caregiver Input). Secondary efficacy variables will include behavioral scales [the&#xD;
      NeuroPsychiatric Inventory (NPI), the Frontal Behavior Inventory (FBI)], cognitive scales&#xD;
      [the Mattis Dementia Rating Scale (MDRS), the MMSE], activities of daily living (Disability&#xD;
      Assessment for Dementia, DAD), time spent by the caregiver of the patient (Resource&#xD;
      Utilization in Dementia, RUD), and caregiver burden scale (Zarit Burden Inventory), and&#xD;
      tolerability of the drug. The main analysis will be carried out on an intention-to-treat&#xD;
      basis in all randomized patients having undergone at least one evaluation after inclusion&#xD;
      (the Last Observation Carried Forward LOCF value, will be attributed to missing values). This&#xD;
      analysis will be carried out at the end of the double-blind study (main judgement criterion)&#xD;
&#xD;
      Expected results and perspectives: The main expected result is the confirmation of the&#xD;
      efficacy of memantine as a treatment for FTD, which would set a precedent in the treatment of&#xD;
      this disease. Such a result could also lead the way to the development of treatments for&#xD;
      other related neurodegenerative disorders (tauopathies) such as the other frontotemporal&#xD;
      lobar degenerations (semantic dementia, progressive non-fluent aphasia), progressive&#xD;
      supranuclear palsy, or corticobasal degeneration. Finally, the standardized follow-up of a 64&#xD;
      patient cohort in this study will provide important information on the natural history of a&#xD;
      rare and poorly-known disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <enrollment type="Actual">52</enrollment>
  <condition>Dementia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>memantine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with FTD based on the criteria defined by the Lund and Manchester groups'&#xD;
             consensus statement (revised in 1998), whose disease has been progressing during the&#xD;
             last year.&#xD;
&#xD;
          -  MMSE score of 19 or higher&#xD;
&#xD;
          -  Men and women aged 45 to 75 years&#xD;
&#xD;
          -  Without speech, visuospatial, or episodic memory impairments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 76 years&#xD;
&#xD;
          -  Illiterate or misunderstanding patients&#xD;
&#xD;
          -  Patients with cancer, heart disease, lung disease, kidney disease (creatinine &gt; 200&#xD;
             mg/dL), or epilepsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine Vercelletto, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre de la Mémoire, Clinique Neurologique CHU Nord Nantes 44093 France; mvercelletto@chu-nantes.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucette Lacomblez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federation de Neurologie AP-HP Paris 75 013 France; lucette.lacomblez@psl.ap-hop-paris.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Dubois, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre du Langage et de Neuropsychologie AP-HP Paris 75013 France; b.dubois@psl.ap-hop-paris.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Sophie Rigaud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Broca, Paris 75 France; anne-sophie.rigaud@brc.ap-hop-paris.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Francois Dartigues, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pellegrin Bordeaux 33 076 France; jean-francois.dartigues@u.bordeaux2.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie Auriacombe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pellegrin Bordeaux 33 076 France ; sophie.auriacombe@u.bordeaux.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Couratier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Dupuytren, Limoges 87000 France; philippe.couratier@unilim.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Touchon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Gui de Chaulliac, Montpellier 34 295 France; jacques.touchon@wanadoo.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthieu Ceccaldi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital de la Timone Marseille 13 005 France; mceccaldi@ap-hm.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mira Didic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital de la Timone Marseille 13005 France; mira.didic@medecine.univ-mrs.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serge Bakchine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Maison Blanche, Reims 51 092 France; sbakchine@chu-reims.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard-Francois Michel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Sainte Marguerite, 13009 France; bmichel@ap-hm.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Thomas-Anterion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Bellevue Saint Etienne, 42 000 France; catherine.thomas@chu-st-etienne.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Laurent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Bellevue Saint Etienne 42 000 France; bernard.laurent@univ-st-etienne.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francois Sellal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Civil Strasbourg 67000 France; francois.sellal@chru-strasbourg.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serge Belliard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pontchaillou Rennes 35 000, France; serge.belliard@chu-rennes.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Herve Allain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Pharmacologie, CHU de Rennes 35 000 France ; Herve.allain@univ-rennes1.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Puel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Purpan, Toulouse 31059 France; PUEL.M@chu-toulouse.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Francois Demonet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Neurologique CHU Purpan Toulouse 31059 France; demonet@toulouse.inserm.fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Sarazin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre du Langage et de la Mémoire, Hôpital de la Salpétriére AP-HP Paris 75013 France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Martine Vercelletto</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2005</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>May 2, 2013</last_update_submitted>
  <last_update_submitted_qc>May 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <keyword>frontotemporal dementia</keyword>
  <keyword>Mémantine</keyword>
  <keyword>Patients with frontotemporal dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

